Corvia Medical has embraced the recent release of V-Wave's RELIEVE-HF trial data, which supports the evidence base for atrial shunt therapy. This therapy is currently under investigation in the global RESPONDER-HF trial of the Corvia® Atrial Shunt.

While the RELIEVE-HF trial did not meet its primary efficacy endpoint and did not demonstrate a reduction in heart failure events or improvement in quality of life among heart failure patients with preserved ejection fraction (HFpEF), the results highlighted the importance of patient selection in determining the efficacy of atrial shunting.

"Patient selection is critical, especially in HFpEF," emphasized Sanjiv Shah, MD, Director of the HFpEF Program at Northwestern University School of Medicine and co-Principal Investigator of RESPONDER-HF. 

"We found in our last trial, REDUCE LAP-HF II, that HFpEF patients with pacemakers or pulmonary vascular disease didn't benefit from atrial shunting. In our ongoing RESPONDER-HF trial, we are excluding those patients and using exercise hemodynamics to qualify and randomize HFpEF patients most likely to respond favorably to shunting," said Shah.

Recognizing the complexity of interpreting trial findings, Martin Leon, MD, Director of Interventional Cardiovascular Care at Columbia University Irving Medical Center and co-Principal Investigator of RESPONDER-HF, stressed the importance of understanding the nuances of different studies. "In this emerging field, it's crucial to recognize the nuances of different studies with respect to patient demographics and trial methodologies to prevent misinterpretation of findings," said Dr. Leon. 

"We know shunting is safe and has a positive effect in appropriately selected patients with HFpEF, and we have three-year data to prove it. We're confident the ongoing RESPONDER-HF trial will be a definitive step forward in bringing atrial shunt therapy to millions of HFpEF patients," added Dr. Leon.

The response from Corvia Medical emphasizes the company's commitment to advancing heart failure treatment through rigorous research and thoughtful patient selection.